Log in

Information on

Adding a talk details

If you have a question about this talk, please contact Claus Bendtsen .

The first AstraZeneca hosted seminar at our Darwin building on the Cambridge Science Park. The seminar will consist of three presentations:

1) A dual fragment/biochemical screening approach to targeting InhA, a Tuberculosis target by Jon Read from AstraZeneca

2) Structure-based design of potent and selective inhibitors of the metabolic kinase PFKFB3 by Judit Debreczeni from AstraZeneca

3) Crystal Structure of a Class C GPCR – metabotropic glutamate receptor 5 (mGluR5) by Andrew Doré from Heptares

This talk is part of the Science@Darwin series.

Note that ex-directory lists are not shown.

The first AstraZeneca hosted seminar at our Darwin building on the Cambridge Science Park. The seminar will consist of three presentations:

1) A dual fragment/biochemical screening approach to targeting InhA, a Tuberculosis target by Jon Read from AstraZeneca

2) Structure-based design of potent and selective inhibitors of the metabolic kinase PFKFB3 by Judit Debreczeni from AstraZeneca

3) Crystal Structure of a Class C GPCR – metabotropic glutamate receptor 5 (mGluR5) by Andrew Doré from Heptares